Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Pain Medicine |
| Vol/bind | 10 |
| Udgave nummer | 8 |
| Sider (fra-til) | 1442-1451 |
| ISSN | 1526-2375 |
| DOI | |
| Status | Udgivet - 2009 |
Emneord
- Det tidligere Farmaceutiske Fakultet
Adgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems-A Delphi study. / Jacobsen, Ramune; Møldrup, Claus; Christrup, Lona.
I: Pain Medicine, Bind 10, Nr. 8, 2009, s. 1442-1451.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems-A Delphi study
AU - Jacobsen, Ramune
AU - Møldrup, Claus
AU - Christrup, Lona
PY - 2009
Y1 - 2009
N2 - ABSTRACT Objective. The aim of this study was to describe the rationale behind the choice of fentanyl administration forms among Danish pain specialists. Methods. Sixty Danish physicians specializing in pain management were contacted via an Internet survey system to perform a two-phase Delphi survey. Response rates were 45% in the brainstorming and 88% in the rating phases, respectively. Statistical analysis with SPSS for Windows 15.00 included descriptive statistics and factor analysis. Results. The most important rationale to choose fentanyl patches was that patients' clinical condition did not allow them to take analgesia orally, while the main explanations for not choosing a fentanyl patch was a specific chronic pain condition such as nonmalignant or neuropathic pain origin, and price. The foremost rationale behind the choice of oral transmucosal fentanyl citrate (OTFC) were cancer patients' need for the alternative to oral, intravenous or subcutaneous rescue medication, followed by patients' wish and ability to administer pain medication independently. The main reasons for not choosing OTFC were price and the argument that OTFC administration requires much energy and healthy patients' mouth and therefore is inapplicable for terminal pain patients. Conclusion. The study had shown that the rationales behind the choice of administration form with fentanyl reported by a panel of Danish pain specialists partly differed from those overviewed in the literature and those thought to be important while developing fentanyl patches and OTFC.
AB - ABSTRACT Objective. The aim of this study was to describe the rationale behind the choice of fentanyl administration forms among Danish pain specialists. Methods. Sixty Danish physicians specializing in pain management were contacted via an Internet survey system to perform a two-phase Delphi survey. Response rates were 45% in the brainstorming and 88% in the rating phases, respectively. Statistical analysis with SPSS for Windows 15.00 included descriptive statistics and factor analysis. Results. The most important rationale to choose fentanyl patches was that patients' clinical condition did not allow them to take analgesia orally, while the main explanations for not choosing a fentanyl patch was a specific chronic pain condition such as nonmalignant or neuropathic pain origin, and price. The foremost rationale behind the choice of oral transmucosal fentanyl citrate (OTFC) were cancer patients' need for the alternative to oral, intravenous or subcutaneous rescue medication, followed by patients' wish and ability to administer pain medication independently. The main reasons for not choosing OTFC were price and the argument that OTFC administration requires much energy and healthy patients' mouth and therefore is inapplicable for terminal pain patients. Conclusion. The study had shown that the rationales behind the choice of administration form with fentanyl reported by a panel of Danish pain specialists partly differed from those overviewed in the literature and those thought to be important while developing fentanyl patches and OTFC.
KW - Former Faculty of Pharmaceutical Sciences
U2 - 10.1111/j.1526-4637.2009.00724.x
DO - 10.1111/j.1526-4637.2009.00724.x
M3 - Journal article
C2 - 19793344
VL - 10
SP - 1442
EP - 1451
JO - Pain Medicine
JF - Pain Medicine
SN - 1526-2375
IS - 8
ER -